ArticleMolecular cancer therapeutics2024

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.

Anran Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.